23. Colistin and Aminoglycosides
Session: Symposium: Repurposing "Old Drugs" to Fight the Current Antimicrobial Resistance Crisis
Wednesday, October 17, 2012: 1:30 PM
George Drusano, MD, FIDSA, University of Florida, Albany, NY

Dr. George L. Drusano is Co-Director of Ordway Research Institute.
After graduating magna cum laude, from the Honors Program at Boston College, Dr. Drusano graduated cum laude, from the University of Maryland School of Medicine in Baltimore. He completed his medical internship and residency at the University of Maryland Hospital, where he was Chief Resident. He was also a Fellow in Medicine in Infectious Diseases at that institution.
Dr. Drusano is a reviewer for prestigious peer-reviewed journals, including the New England Journal of Medicine, the Annals of Internal Medicine, Archives of Internal Medicine, American Journal of Medicine, Journal of Infectious Diseases, the Journal of Antimicrobial Chemotherapy, and Antiviral Research. He was also editor of the section of pharmacology and experimental therapeutics for Antimicrobial Agents and Chemotherapy for 10 years. He is the author of over 180 articles in peer-reviewed journals such as the Journal of Clinical Investigation, Nature Reviews Microbiology, Journal of the American Medical Association, Annals of Internal Medicine, Journal of Infectious Diseases, Clinical Infectious Diseases, Antimicrobial Agents and Chemotherapy, AIDS, Clinical Pharmacology and Therapeutics, Journal of Clinical Pharmacology, and Diagnostic Microbiology and Infectious Diseases.
Dr. Drusano is a Fellow of the Infectious Diseases Society of America and a member of the American Federation for Clinical Research. On the national level, Dr. Drusano was a member of the Interscience Conference on Antimicrobial Agents and Chemotherapeutics (ICAAC) Program Committee, the National Institute of Allergy and Infectious Diseases (NIAID) Ad Hoc Review Group for Drug Discovery for Opportunistic Infection, the NIAID Ad Hoc Review Group for Models for Antiretroviral Therapy in Pregnancy, and the National Human Retroviruses and Related Infections Conference Program Committee. Dr. Drusano has been a member of the Subcommittee on Guidelines for Bacteremia and Endocarditis of the Antimicrobial Agents Use Committee, a joint effort of the Infectious Diseases Society of America and the Food and Drug Administration. He is currently a member of the Program Committee for the IDSA. He has won a number of awards, including being named Distinguished Investigator of the Year (2003) by the American College of Clinical Pharmacology. He also serves as a consultant to NIAID on Biodefense issues. He was named as an ad hoc member to NIAID Council in 2006.
An active researcher, Dr. Drusano has focused on mathematical modeling and the pharmacodynamics of anti-infective chemotherapy, especially the pharmacodynamics of fluoroquinolone antimicrobials, anti-tuberculosis agents and the therapy of biodefense pathogens. For the latter, he was awarded a Program Project Grant of $9.1 million from NIAID Choosing Drug Doses for Biodefense Pathogens.

Previous Presentation | Next Presentation >>

Findings in the abstracts are embargoed until 12:01 a.m. PST, Oct. 17th with the exception of research findings presented at the IDWeek press conferences.